{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:35:09Z","timestamp":1786116909631,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20244Y0100"],"award-info":[{"award-number":["20244Y0100"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62273099"],"award-info":[{"award-number":["62273099"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200090"],"award-info":[{"award-number":["82200090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472795"],"award-info":[{"award-number":["82472795"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22Y11905300"],"award-info":[{"award-number":["22Y11905300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["24ZR1411000"],"award-info":[{"award-number":["24ZR1411000"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023J05297"],"award-info":[{"award-number":["2023J05297"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024J08348"],"award-info":[{"award-number":["2024J08348"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejphar.2026.178838","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:50:07Z","timestamp":1775145007000},"page":"178838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical and immunological significance of FOXO1 as a biomarker of improved response to immune checkpoint plus tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"1021","author":[{"given":"Lingzhi","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7433-8694","authenticated-orcid":false,"given":"Xianglai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178838_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0092-8674(04)00452-0","article-title":"FoxOs at the crossroads of cellular metabolism, differentiation, and transformation","volume":"117","author":"Accili","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.178838_bib2","first-page":"e449","article-title":"A rare finding of a BRAF mutation in renal cell carcinoma with response to BRAF-directed targeted therapy","volume":"8","author":"Banerjee","year":"2016","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2026.178838_bib3","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2026.178838_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2026.178838_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178838_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1084\/jem.20170697","article-title":"Continuous activity of Foxo1 is required to prevent anergy and maintain the memory state of CD8+ T cells","volume":"215","author":"Delpoux","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2026.178838_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108674","article-title":"FOXO1 constrains activation and regulates senescence in CD8 T cells","volume":"34","author":"Delpoux","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2026.178838_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178838_bib9","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C200256200","article-title":"FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress","volume":"277","author":"Furukawa-Hibi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.178838_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2010.10.019","article-title":"FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis","volume":"18","author":"Gan","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2026.178838_bib11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2026.178838_bib12","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-12-3886","article-title":"Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network","volume":"19","author":"Hakimi","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178838_bib13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nri3278","article-title":"FOXO transcription factors throughout T cell biology","volume":"12","author":"Hedrick","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2026.178838_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1084\/jem.20130392","article-title":"Differentiation of CD8 memory T cells depends on Foxo1","volume":"210","author":"Hess Michelini","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2026.178838_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.humpath.2022.07.022","article-title":"The expanding role of BAP1 in clear cell renal cell carcinoma","volume":"133","author":"Kapur","year":"2023","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejphar.2026.178838_bib16","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.immuni.2010.12.002","article-title":"Foxo transcription factors control regulatory T cell development and function","volume":"33","author":"Kerdiles","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2026.178838_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.immuni.2013.07.013","article-title":"The transcription factor Foxo1 controls central-memory CD8+ T cell responses to infection","volume":"39","author":"Kim","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2026.178838_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2026.178838_bib19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178838_bib20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178838_bib21","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.178838_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2009.02.003","article-title":"An essential role of the forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance","volume":"30","author":"Ouyang","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2026.178838_bib23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pe\u00f1a-Llopis","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2026.178838_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2012.01.015","article-title":"Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8+ T cell differentiation","volume":"36","author":"Rao","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2026.178838_bib25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178838_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1068962","article-title":"The essential role of Foxo1 in the regulation of macrophage function","volume":"2022","author":"Rong","year":"2022","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejphar.2026.178838_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2026.178838_bib28","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2026.178838_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1207551","article-title":"PLAC8 is an innovative biomarker for immunotherapy participating in remodeling the immune microenvironment of renal clear cell carcinoma","volume":"13","author":"Sun","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2026.178838_bib30","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1245\/s10434-016-5173-8","article-title":"Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methodology proposed by the International TILs Working Group","volume":"23","author":"Swisher","year":"2016","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.ejphar.2026.178838_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12935-023-03090-7","article-title":"Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics","volume":"23","author":"Tabnak","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejphar.2026.178838_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4049\/jimmunol.1300331","article-title":"FoxO1 controls effector-to-memory transition and maintenance of functional CD8 T cell memory","volume":"191","author":"Tejera","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.178838_bib33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","article-title":"Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial","volume":"23","author":"Vano","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2026.178838_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1541-7786.MCR-16-0176","article-title":"IGF-1 receptor modulates FoxO1-mediated tamoxifen response in breast cancer cells","volume":"15","author":"Vaziri-Gohar","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178838_bib35","article-title":"TPD52L2 as a potential prognostic and immunotherapy biomarker in clear cell renal cell carcinoma","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2026.178838_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1515611","article-title":"Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma","volume":"8","author":"Wang","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejphar.2026.178838_bib37","article-title":"Integration analysis identifies MYBL1 as a novel immunotherapy biomarker affecting the immune microenvironment in clear cell renal cell carcinoma: evidence based on machine learning and experiments","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178838_bib38","doi-asserted-by":"crossref","first-page":"11535","DOI":"10.7150\/thno.45261","article-title":"FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2026.178838_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167869","article-title":"Oxidative stress induces mouse follicular granulosa cells apoptosis via JNK\/FoxO1 pathway","volume":"11","author":"Weng","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2026.178838_bib40","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-17-0686","article-title":"Loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926003201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:49:51Z","timestamp":1786020591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926003201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["S0014299926003201"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178838","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and immunological significance of FOXO1 as a biomarker of improved response to immune checkpoint plus tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178838"}}